Category Archives: Epigenetics

Epigenetics Market 2020: Inclusive Insight

Global Epigenetics Market 2020 provides an in-depth analysis of the current and upcoming market and helps the user to understand theCoronavirus (COVID-19) Impact analysis on marketin terms of its Definition, Segmentation, Market Potential, Influential Trends, and the Challenges that theEpigenetics marketis facing. The Epigenetics industry profile also contains descriptions of the leading topmost manufactures/players like (Illumina, Thermo Fisher Scientific, Merck Millipore, Abcam, Active Motif, Bio-Rad, New England Biolabs, Agilent, Qiagen, Zymo Research, Perkinelmer, Diagenode) which including Capacity, Production, Price, Revenue, Cost, Gross, Gross Margin, Growth Rate, Import, Export, Market Share and Technological Developments. COVID-19 can affect the global economy in three main ways: by directly affectingProduction and Demand, by Creating Supply Chain and Epigenetics Market Disruption, and by its financial impact on firms and financial markets.

>>> To know How COVID-19 Pandemic Will Impact This Market/Industry | Request a Free sample copy of the Epigenetics Market report:

Some of the Major Highlights of TOC covers in Epigenetics Market Report:Chapter 1: Methodology & Scope of Epigenetics Market; Chapter 2: Executive Summary of Epigenetics Market; Chapter 3: Epigenetics Industry Insights; Chapter 4: Epigenetics Market, By Region; Chapter 5: Company Profile; Chapter 6: to show competition and trade situation of Epigenetics Market; Chapter 7: to show the comparison of applications; Chapter 8: to show the comparison of types; Chapter 9: to show an investment of Epigenetics Market; Chapter 10: to forecast Epigenetics market in the next years.

Each segment of the global Epigenetics market is extensively evaluated in the research study. The segmental analysis offered in the report pinpoints key opportunities available in the global Epigenetics market through leading segments. The regional study of the worldwide Epigenetics market included in the report helps readers to gain a sound understanding of the development of different geographical markets in recent years and also going forth. It covers the sales volume, price, revenue, gross margin, historical growth and future perspectives in the market.

Later, the report gives a detailed analysis of the major factors fueling the expansion of Epigenetics Market in the coming years. Some of the major factors driving the growth of the industry are

BuyersSuppliersInvestors End-User Industry

Our exploration specialists acutely ascertain the significant aspects of the global Epigenetics market report. It also provides an in-depth valuation in regards to the future advancements relying on past data and present circumstances of the market situation. In this report, we have investigated the principals, players in the market, geological regions, product type, and market end-client applications. The global Epigenetics report comprises primary and secondary data which is exemplified in the form of pie charts, tables, analytical figures, and reference diagrams. The report is presented in an efficient way that involves basic dialect, a basic outline, agreements, and certain facts as per solace and comprehension.

Key parameters which define the competitive landscape of the Global Epigenetics Market:

Profit Margins Product Sales Company ProfileProduct Pricing ModelsSales Geographies Distribution Channels Industry Evaluation for the Market Contenders

Analysis of Global Epigenetics Market: By Type

DNA Methylation, Histone Modifications, Other Technologies

Analysis of Global Epigenetics Market: By Application

Oncology, Metabolic Diseases, Developmental Biology, Immunology, Cardiovascular Diseases, Other Applications

>>> To get more information on this Premium Report, Click Here @https://www.syndicatemarketresearch.com/market-analysis/epigenetics-market.html

In terms of region, this research report covers almost all major regions of the world, such as North America, Europe, South America, The Middle East and Africa, and Asia-Pacific. Europe and North America are expected to increase over the next few years. In the Epigenetics market, the Asia Pacific region is expected to grow significantly during the forecast period. The latest technologies and innovations are the most important characteristics of North America and the main reason the United States dominates the world market. The South American market is also expected to grow in the near future.

Table of Contents

Part 1 Market Overview1.1 Market Definition1.2 Market Development1.3 By TypeTable Type of EpigeneticsFigure Global Epigenetics Market Share by Type in 20201.4 By ApplicationTable Application of EpigeneticsFigure Global Epigenetics Market Share by Application in 20201.5 Region OverviewTable Region of EpigeneticsFigure Global Epigenetics Market Share by Region in 2020Part 2 Global Market Status and Future Forecast2.1 Global Market by RegionTable Global Epigenetics Market by Region, 2016-2019 (Million USD)Figure Global Epigenetics Market Share by Region in 2020 (Million USD)Table Price List by Region, 2016-20192.2 Global Market by CompanyTable Global Epigenetics Market by Company, 2016-2019 (Million USD)Figure Global Epigenetics Market Share by Company in 2020 (Million USD)Table Price List by Company, 2016-20192.3 Global Market by TypeTable Global Epigenetics Market by Type, 2016-2019 (Million USD)Figure Global Epigenetics Market Share by Type in 2020 (Million USD)Table Price List by Type, 2016-20192.4 Global Market by ApplicationTable Global Epigenetics Market by Application, 2016-2019 (Million USD)Figure Global Epigenetics Market Share by Application in 2020 (Million USD)Table Price List by Application, 2016-20192.5 Global Market by ForecastFigure Global Epigenetics Market Forecast, 2020-2026 (Million USD)Part 3 Asia-Pacific Market Status and Future Forecast3.1 Asia-Pacific Market by CompanyTable Asia-Pacific Epigenetics Market by Company, 2016-2019 (Million USD)Figure Asia-Pacific Epigenetics Market Share by Company in 2020 (Million USD)Table Price List by Company, 2016-20193.2 Asia-Pacific Market by TypeTable Asia-Pacific Epigenetics Market by Type, 2016-2019 (Million USD)Figure Asia-Pacific Epigenetics Market Share by Type in 2020 (Million USD)Table Price List by Type, 2016-20193.3 Asia-Pacific Market by ApplicationTable Asia-Pacific Epigenetics Market by Application, 2016-2019 (Million USD)Figure Asia-Pacific Epigenetics Market Share by Application in 2020 (Million USD)Table Price List by Application, 2016-20193.4 Asia-Pacific Market by ForecastFigure Asia-Pacific Epigenetics Market Forecast, 2020-2026 (Million USD)

Continued.

>>> Make an Inquiry before buying this report @https://www.syndicatemarketresearch.com/inquiry/epigenetics-market

Note In order to provide a more accurate market forecast, all our reports will be updated before delivery by considering the impact of COVID-19.(*If you have any special requirements, please let us know and we will offer you the report as you want.)

Why Syndicate Market Research:

Setting a strong foot in the industry with all planned and tactical approaches is surely not a cakewalk. You need loads of research, analysis, take several factors into consideration, and above all, give your valuable time to the entire process. This is where Syndicate Market Research kicks in as a support system for our clients. Our reports targets high growth emerging markets in the USA, Europe, The Middle East & Africa, and Asia Pacific covering industries like IT and Telecommunications, Machinery & Equipment, Electronics & Semiconductor, Chemicals and Materials, Healthcare & Pharma, Energy & Mining, Manufacturing & Construction, Automotive, Food & Beverage, etc.

Contact Us:

Syndicate Market Research244 Fifth Avenue, Suite N202New York, 10001, United States+1 347 535 0815 |Email ID:[emailprotected]Website:www.syndicatemarketresearch.com

See original here:
Global Epigenetics Market 2020-2026 | COVID-19 Impact & Recovery Analysis Of Key Manufacturers: Illumina, Thermo Fisher Scientific, Merck...

CAMBRIDGE,Mass., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, today announced that the Company will participate in upcoming virtual investor conferences. Jigar Raythatha, CEO, will present at:

Live audio webcasts of Mr. Raythathas presentations and archives for replay will be available on the Investor Relations section of Constellations website at http://ir.constellationpharma.com/events-and-presentations/events. The audio webcast replays will be available for 30 days following the live presentation.

About Constellation Pharmaceuticals

Constellation Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel therapeutics that selectively modulate gene expression to address serious unmet medical needs in patients with cancer. The Company has a deep understanding of how epigenetic and chromatin modifications in cancer cells and in the tumor and immune microenvironment play a fundamental role in driving disease progression and drug resistance. Constellation is driving development of the BET inhibitor CPI-0610 for the treatment of myelofibrosis as well as the EZH2 inhibitor CPI-0209 for the treatment of solid tumors. The Company is also applying its broad research and development capabilities to explore other novel targets that directly and indirectly impact gene expression to fuel a sustainable pipeline of innovative small-molecule product candidates.

Contact

Kia Khaleghpour, Ph.D.Vice President, Investor Relations and CommunicationsConstellation Pharmaceuticals+1 617-844-6859kia.khaleghpour@constellationpharma.com

Ronald Aldridge Investor RelationsConstellation Pharmaceuticals+1 617-714-0539ron.aldridge@constellationpharma.com

Lauren ArnoldMedia RelationsMacDougall Biomedical Communications+1 781-235-3060larnold@macbiocom.com

Follow this link:
Constellation Pharmaceuticals to Participate in Upcoming Virtual Investor Conferences - GlobeNewswire

SALT LAKE CITY, Sept. 9, 2020 /PRNewswire/ --Inherent Biosciences, a biotechnology company headquartered in Salt Lake City, UT, today announced a $255,959 award from the National Science Foundation (NSF) to study epigenetic biomarkers to predict patient response to SARS-CoV2 (COVID-19) infection. The Small Business Innovation Research (SBIR) Phase I project aims to develop an on-site, clinical test to screen incoming patients potentially infected with COVID-19 and prioritize hospital resources and personnel based on a predicted infection severity and treatment response.

The variation in symptoms and outcomes for COVID-19 progression makes it challenging for health care workers to triage patients accurately. The development of a DNA methylation-based test to predict the severity of COVID-19 infection has tremendous potential for managing current and future pandemics.

"NSF is proud to support the technology of the future by thinking beyond incremental developments and funding the most creative, impactful ideas across all markets and areas of science and engineering," said Andrea Belz, Division Director of the Division of Industrial Innovation and Partnerships at NSF. "With the support of our research funds, any deep technology startup or small business can guide basic science into meaningful solutions that address tremendous needs."

Andy Olson, Co-founder and CEO of Inherent Biosciences, remarked: "We're thrilled to announce this award, which will enable us to expand our discovery and commercialization pipeline into the area of infectious disease - a critical area as witnessed by the COVID-19 pandemic we're living through."

The award provides support for Inherent to generate a comprehensive dataset of white blood cell DNA methylation patterns, health history, and clinical data for patients infected with COVID-19. The company then uses artificial intelligence (AI) and machine learning to identify DNA methylation biomarkers predictive of disease severity and treatment response.

Kristin Brogaard, Ph.D., Co-founder and COO of the company, and Principal Investigator for the project added: "Our focus is translating epigenetic discoveries, specifically DNA methylation biomarkers, from research discoveries into commercial products that benefit consumers, patients and health care providers."

Inherent has already translated one epigenetic discovery into a commercial product. The company's first product called "Path" (PathFertility.com) is for couples trying to conceive. Path is marketed directly to consumers as a general wellness sperm DNA test related to maintaining or encouraging a general state of health, specifically male reproductive health.

About Inherent Biosciences- Inherent Biosciences, Inc. is a molecular diagnostics company at the intersection of epigenetics and AI. Inherent believes that guesswork and trial-and-error medicine lead to severe pain and suffering. Inherent's vision is to revolutionize trial and error medicine and restore hope. The company does this by discovering what is inherent in our biology about the unexplained and translating discoveries into personal insights that inform actions. Learn more at http://www.inherentbio.comor connect on LinkedIn.

Contact: Inherent Biosciences, Inc.

Andy Olson, CEO

Phone: (509) 496-1204

Email: andy@inherentbio.com

Related Images

inherent-biosciences-logo.pngInherent Biosciences LogoCompany logo

Continue reading here:
Inherent Biosciences Wins $256K NSF Grant to Predict COVID-19 Infection Severity and Treatment Response - The Herald Journal

SAN DIEGO--(BUSINESS WIRE)--San Diego, Calif.-based biotech company Diomics Corp. is aiming to nose out the novel coronavirus ahead of vaccines by using nanosized biopolymer beads to deliver monoclonal antibody protection against COVID-19 via an easy-to-administer nasal spray.

The Dioguard prophylactic spray, which is now undergoing in vitro testing, pairs Diomics proprietary synthetic biopolymer material with human IgG monoclonal antibodies licensed from another San Diego-area company, Active Motif, Inc., a leader in epigenetic research. The goal is to create a durable barrier of antibodies in the nasal cavity to capture, bind to and neutralize the SARS-CoV-2 virus before it can reach and enter the cells that cause infection. Research demonstrating the potent neutralizing ability of Active Motifs 414-1 antibody has appeared in three peer reviewed journals. http://www.dioguard.com/science

Creating a protective shield that blocks the virus at its crucial first point of entry into the body the nasal passages fills a huge void in the race to develop an effective vaccine for COVID-19. A preventative nasal spray that effectively neutralizes SARS-CoV-2 before it can cause infection we believe holds the key to allowing many aspects of life to resume until the day comes when theres an effective vaccine in widespread use, Diomics CEO Anthony Zolezzi said.

Binding the neutralizing antibodies to our propriety nanobeads extends their residency time in the nasal mucosa to up to 24 hours, enabling people to replenish their protection once a day, Zolezzi said.

Since both human monoclonal antibodies and Diomics biocompatible, bioresorbable Diomat polymer have already received FDA approval for other applications, Diomics plans to seek fast track authorization from the agency to accelerate human trials.

About Diomics

Diomics Corporation is a biotechnology company focused on science-based innovation and the development of life-improving products. Our proprietary Diomat technology platform is optimized for the collection and delivery of compounds and proteins and can also be used for drug delivery, long-term monitoring, diagnostics and production of life-saving hormones and other bio-compounds. Based in San Diego, Calif., Diomics has developed numerous products, tools and services for the molecular, diagnostic and forensic industries. For more information visit diomics.com.

About Active Motif

Active Motif, Inc. is dedicated to developing, manufacturing and delivering epigenetics-based research tools to analyze nuclear function. Its customers include life scientists from academic and government institutions, biotechnology and pharmaceutical companies, hospitals, and reference laboratories. Active Motif operates globally through its corporate headquarters in Carlsbad, Calif. and offices in Shanghai, China; Tokyo, Japan; and Waterloo, Belgium. Active Motif applies a multi-disciplinary approach to create new and modify existing technologies to meet the current and future needs of life science researchers.

NOTE TO EDITORS: Additional scientific background, peer-reviewed research and explanatory video are available at http://www.dioguard.com/science.

See the original post here:
Diomics Aims to Nose Out Coronavirus Ahead of Vaccines With Nasal Spray That Delivers Monoclonal Antibody Protection - Business Wire

Active aging allows individuals to continue to stay involved in the workforce and stay engaged with their pension and savings programs.

Photo: Unsplash

Share this article

Some scientists believe that the firstperson to live to 200 years old has already been born. But counting years on the calendar alone puts the focus on quantity, potentially overlooking quality of life, especially if one cannot be active. Modern medicine and technology can save lives; unfortunately, not as much work has gone into preventing illness as into treating it.

The data shows that as life expectancy continues to increase, people are running out of money for essentials, let alone factoring in the costs of maintaining health and seeking care. The pension gap (between actual savings and income needs) in the U.K. in 2015 was already at $8 trillion, estimated to rise at 4% per annum to reach $33 trillion by 2050. If we look at the top eight global economies, these figures are $70 trillion and $400 trillion, respectively, meaning this is not an isolated problem. In the U.K., at an individual level, this equates to running out of money 10.3 years before you die if you are a man and 12.6 years before you die if you are a woman on average. Can you imagine the gap if we live to 200? For many employees, financial stress is already their number one worry, and 85% tell us that they trust their employers to prepare them adequately for retirement.

Working longer whether its because you have to or want to could close these financial gaps if you have the right information and means, but you need to be active to do so. The fastest-growing employment segment in many developed economies is the over-55s, which means a much larger percentage of older workers are now in employment than ever before. In the U.K., over-55s represented more than 50% of employment growth in the decade to 2018, a trend expected to continue in the next 10 years. Its clear, therefore, that we need to find ways to add healthy years to life, not just years.

Its also clear that what we have done in the past has not solved the problem. We need to enable long-term behavior change to ensure that people enjoy better health and stay active. And thats hard.

Many consider genetics to be the cards we are dealt. Our genes are fixed, and therefore, we are left with the bad and the good that come with them. This may well be true to an extent. However, we have something that sits above the genes known as the epigenome a network of chemical compounds surrounding DNA that have a role in determining which genes are active in a particular cell.

The study of these genetic interactions and changes is called epigenetics, which has become a field of urgent and intense research and may offer us a way of looking at how outcomes can be altered. By changing certain environmental factors such as physical activity, diet, stress and chronic pollution levels lets call these lifestyle interventions your genes may start to behave differently, leading to better quality, more energetic and non-sick aging. This active aging allows individuals to continue to participate in social, economic, cultural and civic activities, as well as remain physically active, stay involved in the workforce and stay engaged with their pension and savings programs. Active aging, therefore, could help minimize, or even eliminate, the funding gap. Additionally, healthy older adults are less at risk of severe consequences of COVID-19.

Muhdo Health has found that by testing individuals epigenetics and applying specific lifestyle interventions, we can expect to see an improvement in their quality of life. Workers get the opportunity to keep working for longer, reduce fatigue and, as a result, enjoy a happier retirement with less worry about the need for care in older (chronological) age.

Many types of workers may benefit from this approach. With the help of epigenetic monitoring, adjustments can be made to workflow, stress management and nutrition and the impact could be measured and controlled.

An employer in the building industry found that its older, more experienced workers were essential to the successful delivery of high-end projects. The continued health of this group of employees was so crucial that the employer implemented a Muhdo measure and monitor process to establish what the right working patterns and interventions should be. Once individuals had been tested and knew the steps they could take to improve their quality of life, they could set their own hyper-personalized goals and put change processes in motion.

Behavior change comes at different speeds not everyone can fix a lifetimes worth of bad habits overnight. But knowing how to add healthy years to your life by understanding your epigenetics may certainly help drive behavior change in a positive direction.

In addition to helping employees identify individual action plans, this employer found that it could help further by adjusting work and shift patterns to allow for more flexibility for this group of older, more experienced workers. Creating more flexibility reduced stress levels and improved engagement. This type of flexible work in later life is becoming increasingly prevalent. More than three-quarters (76%) of employees in Mercers 2020 Global Talent Trends Study said that they intended to continue working in some shape or form beyond the official retirement age, and 24% planned to work fewer hours. Up to 57% of employers already offer part-time work pre- and post-retirement as a means to embrace the value of older workers, and 46% are building a pool of retiree talent to tap into. These approaches could become even more useful for everyone by adding healthy active years to the mix.

And if a simple saliva test (repeated at intervals, say, quarterly or annually) could enable a future with less back pain, fewer muscle aches and injuries, less sickness, and even improved mental health as a result of better physical health then workers and employers rejoice!

We believe there are two key learnings to take forward:

Proactive epigenetic testing can enable employees to enjoy more healthy and active years. Epigenetic testing could be the way to unlock much-needed behavior change and the adoption of smarter lifestyle choices.

Flexible working arrangements can reduce stress, and improve productivity and financial resilience, closing the income gaps referred to earlier. They can be even more effective closer to retirement to allow for working in later life and retaining critical experience and skills.

Epigenetics research and the implications of lifestyle-related changes in the cause of disease and aging holds great promise. It could unlock our understanding of how an individual responds to environmental cues and acquired risk factors. It also raises profound ethical questions about the role of the employer and the efficacy of workplace programs and conditions and their unintended consequences.

Read the original here:
Active Aging Could Eliminate the Retirement Funding Gap With the Help of Epigenetics - BRINK

- Genomics analysts Muhdo and bioelectronics experts NuroKor to launch personalised health profile KorDNA

- With a simple saliva test, users can access personalised health and lifestyle advice that could unlock the human body's full potential

- By combining big data DNA analytics the platform is set to provide bespoke bioelectrical treatments to suit a user's own genomic sequencing

LONDON, Aug. 26, 2020 /PRNewswire/ -- In the first partnership of its kind, two healthtech startups NuroKor and Muhdo have announced a collaboration to bring together the science behind bioelectronics and DNA data sequencing to personalise the recovery processes that occur post-workout, injury, and illness.

Muhdo's DNA and epigenetic analysis allows for a personal understanding of your own recovery and inflammation and NuroKor's devices help you take control of it. Using scientifically-proven, personalised bioelectronic medicine, NuroKor can support pain management and injury rehabilitation, as well as improving recovery from exercise and training.

As healthcare moves towards individualised treatments, so too does wellness and training. Muhdo provides all the information needed to build a data-driven, customised approach to rehab, prehab and performance. This, supported by the NuroKor BioElectronic system, can allow consumers to track the impact of Electrical Muscular Stimulation (EMS), and assist them in boosting results, whilst tracking biomarkers that identify inflammation and epigenetic age.

KorDNA has been developed with a focus on personalisation. The non-invasive saliva test provides users with detailed insight into their own DNA profile and an understanding of how environment and lifestyle can affect genetic expression, as well as personalised health recommendations including tailored workout plans and nutrition, training, treatment and recovery guides. With this detailed and highly individualised information, users are supported to meet their own health needs and goals.

Commenting on how improved awareness of genetic factors could aid with injury and exercise recovery, Dr Leah Austin, GP and Nutritional Therapist said:

"The ability to build a bespoke management plan using a NuroKor device, which is based on an in-depth understanding of personal genetic disposition has the potential to profoundly improve recovery from training for people exercising at all levels. I know from my own personal and professional experience that some people's bodies take much longer to rest and repair from strenuous activity. I once cycled from Lands End to John O'Groats and experienced significant swelling, also known as oedematous - at the time I didn't have a recovery plan but if I'd had a routine that took into consideration my genetics using a simple and effective device like NuroKor, my experience could've been very different."

Through continued collaboration, the two startups are already exploring new ways to integrate bioelectronics into DNA profiling to assist with even more highly personalised treatment protocols foroptimal pain treatment or increased training performance and muscle development.

"Epigenetics is the science that explains how your genes behave. You are born with your genetic makeup, but how those genes are expressed is affected by lifestyle," explains the Chief Executive of Muhdo, Nathan Berkley. "Our partnership with NuroKor and the development of the KorDNA profile will allow users to monitor core areas of their health, diet and vitamin levels, psychology, and physical condition to provide a means to better understand their body and maximise its potential."

Building on this Rick Rowan, CEO and Founder of NuroKor BioElectronics comments: "By collaborating with Muhdo, we can better understand the epigenetic factors that impact individuals. Together, we will be able to provide personal, easy-to-understand DNA diagnostics and real-time user sensor analytics via the app - the combination of our bioelectronic treatment applications and Muhdo's data analytics has the potential to improves lives, whether your aim is to recover from injury or illness, or to simply get fitter."

KorDNA is available to buy starting at [99] at http://www.nurokor.co.uk

NOTES TO EDITORS

If you would like to interview Rick, Leah or Nathan contact:

somX

James Somauroojs@somx.com

Houston

Alexander ClellandFiona Callmuhdo@houston.co.uk 0203 701 7660

For imagery, please access available images via here.

About NuroKor

Founded in 2018, NuroKor is a business committed to the development of bioelectronic technologies. NuroKor develops and formulates programmable bioelectronic software forclinical and therapeuticapplications, in a range of easy to use, wearable devices. It provides the highest-quality, medically regulated products, delivering personalised pain relief and recovery support and rehabilitation to patients.

About Muhdo

Muhdo is the first company in the world to offer a true internal wellness epigenetic profiling programme direct to companies and consumers, inspiring and supporting people to live healthier, happier, longer lives. As a next generation genetic and big data company, its vision is the mass personalisation of preventive and curative health through epigenetics and analytics, delivering a truly holistic and objective health and wellness programme.

https://nurokor.com

SOURCE Nurokor; Muhdo

See the original post:
New healthtech partnership set to unlock the power of personalised bioelectrical treatment using DNA sequencing - PR Newswire UK

Fort Collins, Colorado Reports Globe recently published a report on the Epigenetics Market. The study was supported by data obtained either from primary sources or from corporate databases. The experts in the market have confirmed that the data is realistic and relevant to the particular market conditions and therefore will prove extremely helpful to the user. The factors that have been broken down into driver and restraint systems. The regions, types, applications, and strategies are segmented and subdivided for better and better understanding.

This report covers the current economic impact of COVID-19. This outbreak drastically changed the global economic situation. The current scenario of the constantly evolving corporate sector, as well as the present and future assessment of the impact, are also addressed in the report.

Epigenetics market garnered a revenue of USD 7.4 billion in the year 2019 globally and has been foreseen to yield USD 30.1 billion by the year 2027 at a compound annual growth (CAGR) of 18.9% over the forecast period.

The Epigenetics marketreport gives a 360 approach for a holistic understanding of the market scenario. It relies on authentically-sourced information and an industry-wide analysis to predict the future growth of the sector. The study gives a comprehensive assessment of the Epigenetics industry, along with market segmentation, product types, applications, and value chain.

Leading Epigenetics manufacturers/companies operating at both regional and global levels:

F. Hoffmann-La Roche Ltd

The report also inspects the financial standing of the leading companies, which includes gross profit, revenue generation, sales volume, sales revenue, manufacturing cost, individual growth rate, and other financial ratios.

Research Objective:

Our panel of trade analysts has taken immense efforts in doing this group action in order to produce relevant and reliable primary & secondary data regarding the Epigenetics market. Also, the report delivers inputs from the trade consultants that will help the key players in saving their time from the internal analysis. Readers of this report are going to be profited with the inferences delivered in the report. The report gives an in-depth and extensive analysis of the Epigenetics market.

The Epigenetics Market is Segmented:

Epigenetics Market, By Technology (2016-2027)

Epigenetics Market, By Application (2016-2027)

Epigenetics Market, By Product (2016-2027)

This Epigenetics report umbrellas vital elements such as market trends, share, size, and aspects that facilitate the growth of the companies operating in the market to help readers implement profitable strategies to boost the growth of their business. This report also analyses the expansion, market size, key segments, market share, application, key drivers, and restraints.

Epigenetics Market Regional Analysis:

Key Coverage of Report:

Key insights of the report:

How Reports Globe is different than other Market Research Providers

The inception of Reports Globe has been backed by providing clients with a holistic view of market conditions and future possibilities/opportunities to reap maximum profits out of their businesses and assist in decision making. Our team of in-house analysts and consultants works tirelessly to understand your needs and suggest the best possible solutions to fulfill your research requirements.

Our team at Reports Globe follows a rigorous process of data validation, which allows us to publish reports from publishers with minimum or no deviations. Reports Globe collects, segregates, and publishes more than 500 reports annually that cater to products and services across numerous domains.

Contact us:

Mr. Mark Willams

Account Manager

US: +1-970-672-0390

Email:[emailprotected]

Web:reportsglobe.com

View post:
Epigenetics Market Size and Growth 2020-2027 | Major Players Qiagen, Novartis AG, Active Motif, Merck Sharp & Dohme Corp, Thermo Fisher...

]]]]]] Volitions CEO, Cameron Reynolds spoke to Medical Technology about the companys story so far and what sets their technology apart from others in development. Credit: Volition

Sign up here for GlobalData's free bi-weekly Covid-19 report on the latest information your industry needs to know.

Epigenetics company Volition is hoping to carve new ground in the cancer diagnostics space. Through measuring tumour nucleosomes (a type of epigenetic structure) in the blood, it is creating a range of blood tests that can detect cancer from the earliest stages. The company says these tests will be simple, cost-effective and easy to use.

With clinical trials underway, the company is now focused on bringing its toolbox of diagnostic products to market. Volitions CEO, Cameron Reynolds spoke to Medical Technology about the companys story so far and what sets their technology apart from others in development.

Abi Millar (AM): Whats the story behind Volition? Can you tell me a bit about your path to getting where you are today?

Cameron Reynolds (CR): We started ago nearly ten years ago, in September 2010. Were still using the same technology platform as we were then a lot of companies chop and change, but weve always believed in epigenetics and see them as really important in cancer diagnosis.

We started with one original patent application, which was licensed to us from Chroma Therapeutics. We wanted to commercialise this basic concept of using nucleosomes (a type of epigenetic structure) for a marker for cancer detection, and eventually a number of other diseases as well. So we set up a subsidiary in Belgium, which we felt was a good value place to develop research, and raised just over a million euros. We also have offices in Texas, London and Singapore.

Our whole ethos has been to make low-cost, routine cancer diagnostics with an ELISA based format. The ELISA platform is 35 years old our chief scientific officer Jake Micallef has been working on this format his entire life, and hes a big believer in keeping it affordable.

We started with our original patent, which was histone modifications, and then we patented everything else we did along the way, so we have very strong intellectual property. We began with diagnostics for human cancers, starting with colorectal, and then adding in lung cancer and some other cancers where weve had some good results.

Around two and a half years ago, we expanded the staff and moved into a bigger facility in Belgium. We now have 35 people working there, attempting to create a robust, reliable stable platform to measure the tumour nucleosomes in circulation. We went public in 2015 on the New York Stock Exchange, since the capital markets are quite a good source of funding if you have something new and innovative.

Since then weve just been swimming in our own lane, developing our technology. Were in the process of launching a range of products over the next few years, and hopefully we can really do a good job with it.

AM: You are developing a range of blood tests for cancer diagnostics called Nu.Q, which has been described as an epigenetic toolbox. What is Nu.Q exactly? How does it work?

CR: We have several different ways of analysing the nucleosomes, ranging from a very simple microtitre plate-based ELISA format to a magnetic bead-based ELISA format. The new process were developing now, called Nu.Q Capture, involves capturing the nucleosomes on the machine, isolating them from the plasma, and conducting mass spectrometry analysis. This enables a greater concentration of nucleosomes.

Were using Nu.Q for our own purposes in cancer trials and other trials, and have also partnered with Texas A&M Veterinary School to find out whether our basic format could be useful in veterinary science too. Thats why we call Nu.Q a complete toolbox. Its a very robust reliable platform that can be used in all these different areas, and its a whole new way of analysing the epigenetic structures.

AM: What is different about this method, compared to other diagnostic assays for cancer?

CR: Since we started, there have been a lot of different cancer diagnostics in development, based on circulating tumour cells, DNA, exosomes, etcetera. But were still the only group ever to have looked at nucleosomes in circulation as a diagnostic.

We also have the ethos to keep it very affordable and easy to use. With a lot of companies its a complicated, expensive technology circulating DNA for instance requires a very large blood draw and quite expensive processes. Weve kept it simple, and we can do that because the markers were after are common in the blood and you can measure them with a simple ELISA format.

So theres always space for lots of different methods, but we think theres a very strong need for a low cost, reproducible reliable test that can be taken by huge numbers of people around the world as part of their normal medical work. That makes us unique not only in terms of the markers were after the nucleosomes but also in terms of the basic ethos. Weve spent the last two and half years fully optimising the platform itself so it can be robust, reproducible and reliable and accessible to any lab in the world.

AM: You currently have a number of clinical trials underway and presented some initial data at the 2020 ASCO Annual Meeting. What might the path to the clinic look like?

CR: We now have some markers that have shown very good efficacy in a range of cancers, but were also looking for differential markers between the different cancers. Were running some smaller trials for lung, colorectal and blood cancers some of the data was released at ASCO and now were putting together panels of those to get enough accuracy for a frontline test.

We also have some larger trials, like the early detection research network in the US, which will involve around 7,000-8,000 people. There are also some in Taiwan for lung and colorectal cancers, which will involve around 8,000-9,000 altogether.

So, weve got small and medium-sized trials along with some very large product trials. Thats on top of the trials we have in the veterinary space, as well as trials for things like Nu.Q Capture. Weve also had some very encouraging data in Covid-19, where were looking at prognostic outcomes.

Our assays are very low cost and easy to run with small amounts of blood, so we can run them in lots of different areas. There should be a lot of results coming through this year, next year and into 2022.

AM: What are your hopes for the future? What could the implications of your technology be further down the line?

CR: My hope is that our kits will enable much earlier diagnosis. That would really help to lower costs both in human terms and financially. If you get diagnosed early, you can survive it a lot longer of those diagnosed in stage 1, about 95% survive five years or more whereas its exactly the opposite if the cancer is found in stage 4. Thats obviously horrible for yourself and your family but its also a financial burden for health systems.

So hopefully it will have a very strong human impact on limiting the severity of the disease, as well as saving health systems and individuals money. This will make it affordable for healthcare systems in the developed and developing world, so we can hopefully save lives worldwide. And what we hope is that in five years, a large percentage of the worlds population who are either of age or at risk take our blood tests through routine blood work and we can do a lot of good in a lot of different areas.

AM: More generally, what do you expect the future of blood testing for cancer to look like?

CR: I certainly hope the other tests succeed, because particularly in markets like the US where there is an appetite for expensive tests, I think they could be very useful and some of them could be very accurate. So thats always a good thing, but what were providing is a routine, easy to use, lower cost alternative.

I think there are going to be things happening at both ends of the market, both at our end and also at the more complicated end of the market. A lot of it will be based on the epigenetics and not just the DNA the complete package of the epigenetics, the nucleosomes and the whole chromosome will make a big difference.

So, there are quite a few things in development that may work and I think theres going to be a real revolution in cancer diagnostics over the next five years. People will be able to get blood tests to get diagnosed early and hopefully well be a part of that.

Read the rest here:
Q&A: discussing cancer blood testing tech with Volition - Verdict Medical Devices - Medical Device Network

Cambodian director Rithy Panh survived the brutal Khmer Rouge regime that took the lives of many of his friends and family. His latest film Irradiated, which premiered in competition at the Berlin International Film Festival, does not shy away from human horrors like those he experienced in his youth.

The film pieces together brutal black-and-white archival war footage spread across a tryptic of panels, juxtaposing footage of Hitler with the devastation of Hiroshima and a basket of decapitated heads, or executions and mass burials.

Irradiated is a difficult, visceral viewing experience an artistic choice that Panh pondered seriously, he said in a recent masterclass at the Sarajevo Film Festival moderated by Variety.

Of course theres a moral question. Why do you want to show this body? Its possible to show a body, or not to. Its a difficult [decision] in both the selection and editing process, Panh acknowledges. Why this [image] and not another one? And why at this place and not another place?

Panh reflected on the work of Claude Lanzmann, who chose not to use gruesome archival footage in his iconic documentary Shoah, and Alain Resnais, who did in Night and Fog, excerpts of which appear in Irradiated. In the end, he decided to make use of such imagery because it helped him delve deeper into his understanding of his own dark past, and the broader question of human evil.

I watched a lot of images and decided to use only those that had an echo on me, that I came to [having had] the same experience, he said.

The choice to use disturbing footage of Nazis tossing corpses from recently liberated concentration camps into a mass grave, for instance, was a difficult one. I did it myself in another context, says Panh, who was forced as a young man to bury bodies in the same fashion. Its a scene for me about why we dont respect [them] more, these bodies? If an image echoes or resonates in my mind, I assume the responsibility to edit it.

History, for Panh, thus becomes raw material for personal inquiry. He feels it justifiable to submit viewers to such a disturbing onslaught because his creative act of filmmaking is itself a defiance of such violence, and a step in the process of rebuilding himself.

Creativity is a fight against the destruction, he said.

When he started working on Irradiated, he spent nearly two years of work on the film in Japan speaking with the hibakusha the irradiated people, as Panh calls them who are the surviving victims of the atomic bombings of Hiroshima and Nagasaki.

An encounter with lab mice at an epigenetic research lab in Zurich, however, changed the entire direction of the film. Whereas normal mice will try to swim when placed in water, the descendants of traumatized mice will give up quickly, allowing themselves to drown and die, he cites. After discovering epigenetics, when I got back to the film it was a whole other thing, he said.

Cinema is important for me, says Panh. It reverts [traumatic] processes for me and teaches me how to swim. Irradiated is perhaps a way for me to understand, maybe, my own situation, and what I can do to not transmit this trauma.

When asked about a present atrocity, the ongoing incarceration and oppression of the Uighur people in Chinas northwestern region of Xinjiang, Panh, one of cinemas foremost chroniclers of genocide, did not have any comment specific to that situation.

He instead broadened his response to condemn the way digital media cuts us off from opportunities for the type of deep reflection needed to live harmoniously together and to create great cinema.

For me, its more than [just a matter of] country; the digital also censors us a lot, he said. When information moves too quickly, there is no time for reflection, leading people to be easily manipulated, he explained. Now people want immediate pictures, immediate info, [but] you need time to analyze, to watch, to step back. Its become a way to censor a diversity of points of view.

Panh, by contrast, is a fan of taking things slow.

He was supposed to start shooting a new film in March, but has grounded those plans for now while it remains impossible to travel due to COVID-19. The pandemic has given him time to stop and talk to his vegetables in the garden and notice the increase of birdsong in Paris. Hes mulling his next projects, which include a documentary on the symbolic use and commercial exchange of Cambodian statuary, and perhaps new ventures inspired by COVID on how animals come to take power in cities as they empty of human presence, or the rise of totalitarian governance tactics in response to the virus.

Cinema is on death row now, he added. Modern filmmaking is all about speed, he assesses, and the movie industry puts more money in digital platforming and less and less towards cinema as literature. One day we will all be dead from this kind of lack of reflection.

See the rest here:
Cambodias Rithy Panh Discusses the Ethical Quandaries of Irradiated at the Sarajevo Film Festival - Variety

It seems like only yesterday that Claudia Schiffer and her supermodel colleagues Cindy, Linda, Naomi and Christy ruled the runwaysin the 1990's. But in reality, it's been a good few decades since the original 'supers' reigned supreme.

Still, it's those same faces that many of usGen X'ers continue toaspire to, especially as many of them are now in their 50's- and looking better than ever - without obvious cosmetic procedures or surgery.

Claudia Schiffer turns 50 today, yetshe could easily be mistaken for someonein her 30's. Of course she does, she's got ridiculouslygood genes, I hear you scoff. Ah,but it's not as simple as allthat.

While there is no doubt that Claudia won the facial lottery, there's plenty of 'traditionally' beautiful starlets whose lookshave crumbled under the accumulationof life's many stresses - and some typically ordinary faces who have grown more youthful looking with age.

The common denominator in looking good, it seems, is lifestyle -or to be fancy about it, epigenetics: the effects thatour external lifestyle choices have on our perceived age.

Claudia's attitude to ageing is a holistic one. She believes in taking care of herface with natural organic skincare, eating healthily, exercisingandbeing out in nature. Which would explain why she's teamed up with organic lifestyle brand,Bamford, to launch an exclusive limited editionbeauty bag to celebrate her 50th birthday - a chosen edit of theactual products that Schiffer has been using on her face and body for years.

I was dying to know what's inside her limited edition collectionso that I can slap it all on in a bid to reach 50 looking half as youthful as she does, and I suspect you're curious too.

The bespoke bag designed by Carole Bamfordand Claudia contains a selection of five daily skincare and wellness essentials that are inClaudias beauty regime tocelebrates'the confidence that comes with age when you look after your health and well-being.'

Claudiasays, 'Im thrilled that in celebration of my 50th birthday Bamford have curated the products I use in my daily routine,into a limited-edition set, complete with a bespoke Claudia beauty bag. I love natural skincare and have used Bamfords products for years. They contain no harmful chemicals or preservatives, feel luxurious and are effective. Their organic and sustainable ethos is also very important to me.'

See the original post here:
As Claudia Schiffer turns 50, we reveal the skincare products she actually uses - Telegraph.co.uk